trending Market Intelligence /marketintelligence/en/news-insights/trending/Y1o3Q7WBl9t_MG2ekxhNpw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

InnoCare Pharma files for Hong Kong IPO

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


InnoCare Pharma files for Hong Kong IPO

InnoCare Pharma Ltd., a Beijing-based company developing therapies for cancer and autoimmune diseases, filed for an IPO on the Hong Kong stock exchange.

The company's pipeline consists of cancer drugs orelabrutinib, ICP-192 and ICP-105. InnoCare is evaluating orelabrutinib in China and the U.S. for treating various blood cancers and autoimmune diseases.

InnoCare plans to file for Chinese approval for orelabrutinib in late 2019.

The company said it has no products approved for commercial sales and has not generated revenues from product sales. InnoCare incurred operating losses of 321.9 million Chinese yuan for the six months ended June 30.

Morgan Stanley Asia Ltd. and Goldman Sachs (Asia) LLC are the joint sponsors for the offer.

In December 2018, InnoCare raised about $160 million in a financing round led by private equity firms, including Loyal Valley Capital, 3H Health Investment Management and Epiphron Capital.

The company raised about $215 million in total financing in 2018.

As of Oct. 16, US$1 was equivalent to 7.09 Chinese yuan.